微博(09898.HK)迴應或被美國強制除牌 稱正繼續監察市場發展
美國證券交易委員會(SEC)宣佈更新《外國公司問責法案》(HFCAA)臨時發行人名單,將微博-SW(09898.HK)(WB.US)列入名單,成爲第六間被美國威脅除牌的美國上市中國公司。微博迴應指會繼續監察市場發展,及評估所有策略選項。
根據該法案,被列入名單的公司有除牌風險,若連續三年未能遵守審計要求將被退市,而微博提交申辯證據截止時間爲4月13日。
SEC於本月8日公佈首批列入名單的五間中國企業,包括百濟神州(06160.HK)(BGNE.US)、百勝中國(09987.HK)(YUMC.US)、再鼎醫藥(09688.HK)(ZLAB.US)、ACM Research(ACMR.US),以及和黃醫藥(00013.HK)(HCM.US)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.